According to Dominguez-Valentin (2020), a female LS patient with a MLH1 PV is estimated to have a 37% cumulative risk of endometrial cancer by age 75, whereas if they instead carried an EPCAM PV, then their risk would only be around 13%. The gene discussed is MLH1; the disease is endometrial cancer.